effect of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). 4 Approximately 40% of lung adenocarcinomas appear somatic mutations within the tyrosine kinase (TK) domain of EGFR. 5 In most published reports, exons 18-21 were the activated mutations in EGFR of lung adenocarcinomas. Deletions in exon 19 ((most frequently E746-A750) and the L858R missense mutation in exon 21
(Leu858Arg) occurred approximately 80% of lung adenocarcinomas. 6, 7 The status of EGFR mutation is the critical biological factor for patient to select proper drugs.
It is well known that the surgery or biopsy tissues for ARMS analysis are the main resource for EGFR mutation analysis. However, it is difficult to get the sufficient tumor tissue of NSCLC patients. What is more, the methods are invasive and many patients could not tolerate it. On the contrary, plasma DNA is considered to be a possible alternative to tumor tissue and it might provide a noninvasive method of analyzing EGFR mutation. [8] [9] [10] Some reports showed the consistency of EGFR mutation detection rate in tissue specimens and blood samples was 50%-70%.
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Circulating single-molecule amplification and resequencing technology (cSMART) was firstly applied in the noninvasive prenatal testing (NIPT) for detecting mutation fetal alleles circulating in the maternal plasma. 12 It preamplified single allelic molecules with unique barcodes. With only counted once, cSMART eliminated potential PCR size bias and got more precise quantitation of the mutant allele percentage in plasma sample. 12 What's more, it was designed specifically to detect station of EGFR mutations in plasma of NSCLC patients with advanced. 13 However, whether some clinical characteristics affected the accuracy of cSMART technique is still unclear. In this study, we compared different clinical characteristics affected the sensitivity, specificity, accuracy, positive predictive value (PPV) and negative predictive value (NPV) of cSMART for detection EGFR mutation from 95 patients with lung adenocarcinoma.
| MATERIALS AND METHODS

| Study design
It was a single-center study, initiated at the Henan Cancer Hospital affiliated with Zhengzhou University. All patients enrolled were older than 18 years. The patients were newly diagnosed with lung adenocarcinoma by biopsy or surgery. The included patients had not undergone any treatment before. Tumor tissue and matched plasma were stored for EGFR mutation analysis. All patients in this study signed informed consent forms to participate it and written permission for using their samples. The study was approved by the Institutional macroscopically, and scalpel-dissected. According to the proportion of the tumor cells, the number of sections were used for DNA extraction from five to ten. For each patient, blood samples were collected with 5 mL and centrifugation was performed at 3000 rpm for 10 minutes.
Then, the plasma was separated and stored at −80°C.
| DNA extraction from tissue sections
Tumor tissue DNA was extracted from formalin-fixed, paraffinembedded (FFPE) specimens. FFPE sections were deparaffinized in xylene and rehydrated in descending grades of absolute ethanol.
According to the instructions of the manufacturer, DNA was extracted using an AmoyDx FPPE DNA Kit (Amoy, Xiamen, China). The genomic DNA was digested by 20 μL proteinase K at 55°C overnight and eluting in water.
| DNA extraction from plasma
Plasma DNA was isolated through a QIAamp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany), according to the manufacturer's protocol. All genomic DNA was stored at −80°C until use.
| DNA quality assessment
Using a Nano UV spectrophotometer to detect the quality of DNA.
Ensure the OD 260/280 values were between 1.8 and 2.0.
| EGFR mutation by ARMS assay
Human EGFR Mutation Detection Kit and real-time PCR (Agilent StrataGene Mx3000P, Palo Alto, CA, USA) were used for EGFR mutation. The PCR reaction processed three stages: 5 minutes incubation at 95°C, followed by 15 cycles of 95°C for 25 seconds, 64°C
for 20 seconds and 72°C for 20 seconds. Fluorescence was measured at 60°C. The ARMS method could be validated to detect a mutation as low as 1.0%.
| EGFR mutation by cSMART assay
According to a previously described protocol, counting of uniquely barcoded single allelic molecules in plasma to determine fetal DNA fraction was performed using a 76-SNP multiplex cSMART assay. 13 The sequences of primers for EGFR exon 18 to 21 were strategically designed (including G719X in exon 18, deletions mutations in exon 19, T790M mutation in exon 20, exon 20 insertions, and L858R in exon 21, L861Q and S768I). 
| Statistical analysis
| RESULTS
| Patient characteristics
In this study, 95 patients were enrolled at Henan Cancer Hospital.
There were 51 were females and 44 were males, with a median age Table 1 .
| Comparison of the sensitivity and specificity of EGFR mutation status in plasma and tissue
Tissue and plasma mutation were respectively detected using ARMS and cSMART method. tissue and plasma which were adopted ARMS and cSMART to detect EGFR mutation were showed in Table 2 (Table 4) .
| DISCUSSION
The curative effect of EGFR tyrosine kinase inhibitors (EGFR-TKIs) is closely related to the EGFR mutation status. Sometimes, it was difficult to obtain enough tumor cells to detect EGFR mutation status by amplification block mutation system (ARMS) method. In addition, it is also an invasive and painful process for patients. Hence, it is hard for those lung adenocarcinoma patients to carry out individualized treatment. In recent years, plasma DNA is considered to be a possible alternative to tumor tissue for detection gene mutations. However, the results about the consistency of EGFR mutation between tissue specimens and plasma samples was approximately 50%-70%. 11 Recent study have shown that circular single molecular amplification and resequencing technologies (cSMART) could successfully detect gene mutation in plasma. 13 However, few studies reported the association between difference of clinical characteristics and the consistency of cSMART.
Deletions in exon 19 and L858R point mutations were the most common mutations, which accounted for approximately 90% of all EGFR mutations. 6,7 L861Q point mutations, S768I point mutations, G719X point mutations and T790M were less common mutations in EGFR mutation types. [16] [17] [18] [19] In recent studies, reported deletions in exon 19 frequently occurred in younger patients and L858R point mutations frequently occurred in older patients. 20 Our results showed that cSMART had more accuracy in exon 19 than L858R point mutation.
But the reason for this remains unclear.
In our study, lung adenocarcinoma patients with EGFR mutation showed differences sensitivity, specificity and consistency ratio of cSMART among clinical characteristics. cSMART technology has higher ration on the lung adenocarcinoma patients with younger than 60 years. Besides, they are more likely to have high consistency ratio in metastasis group than non-metastasis group. Through multivariate analysis, we confirmed our findings. And there was no statistically difference among other aspects we observed in this study.
Zhou et al. 21 reported the detection consistency rate in biopsy specimens was lower than in surgical specimens by direct sequencing and by ARMS for detection EGFR mutation status. Interestingly, we got the opposite results. In this study, the detection consistency for the biopsy samples is higher than surgery samples, which was 87.1% and 65.5%, respectively. When the specimen includes large numbers of normal cells, the detection rate of methods might decrease. 22 In our study, amount of the specimens were in advanced stage. That might the main cause which leaded the consistency of cSMART in biopsy was higher.
Circulating free DNA (cfDNA) is the degradation of DNA fragments which is released into the plasma. 23 The free DNA fragments of plasma derived from normal cells and tumor cells known as ctDNA. 24 Depending on the different tumor stage and tumor loading, ctDNA accounted for the proportion of all cfDNA from 1% to 93%. 8, 25, 26 The traditional generation sequencing technology almost could not detect ctDNA in plasma because of the low level. However, the plasma mutations in advanced NSCLC patients are properly detected. 27 Board et al., demonstrate the detection of ctDNA mutations is lower in the early stage disease than more advanced stage and feasibility utility of PIK3CA mutation detection of plasma in patients with metastatic breast cancer. 28 Our results showed the ratio of sensitivity, specificity and accuracy of cSMART are 92.9%, 77.8%, and 87.0%, respectively, which are higher in metastasis patients. Therefore, cSMART T A B L E 3 Sensitivity, specificity, consistency for cSMART in different clinicopathologic characteristics could help better prognosis in metastasis patients. As we known, cfDNA can be detected in the blood and various bodily fluids. 29 The circulation between the release and degradation of cfDNA appears in healthy person. The previous evidence show cfDNA enters the blood mainly through a mix of apoptosis, necrosis, autophagy, or mitotic catastrophe. 30 The broken circulation of cfDNA might be the primary cause. 31 The correlation between age and cfDNA content has not been reported. Interesting, we found the sensitivity, specificity, and consistency of cSMART was more high in younger than 60 years patients in our study. We speculate that it may be due to the lower 37 What's more, the advantage of cSMART could be possible to design specific primer for the discovered oncogenes to detect genotypes of tissue and plasma in cancer patients. 13 In our study, we detected more samples with less frequency mutant point in plasma by cSMART than tissue sample by ARMS. We consider the difference may be attributed to the metastasis stage and specimen type (surgical or biopsy). One patient with T790M mutation detected in plasma which was not in the tissue was in an advanced stage, with distant metastasis. In our study, we found there was a positive correlation between metastasis stage and consistency of cSMART. And these specimen types were biopsy specimen. Although our date showed the consistency of cSMART for the biopsy samples is higher than surgery samples, the biopsy tissue still contains a small number of tumor cells and presences tumor heterogeneity which could not reveal the genome map of cancer. 38 However, ctDNA which includes all aspects of the tissue heterogeneity could reflect all genome of cancer. 39 In conclusion, we demonstrated the sensitivity, specificity, accuracy of cSMART for detection EGFR mutation in plasma samples of lung adenocarcinoma patients with different clinical characteristics.
Moreover, detection for plasma EGFR mutation status using cSMART might have higher accuracy in the lung adenocarcinoma patients with younger than 60 years and metastasis.
